EPIRUBICIN FOR INJECTION 2 MG — DIN 02324091
EPIRUBICIN HYDROCHLORIDE : 2 MG · TEVA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is EPIRUBICIN FOR INJECTION?
EPIRUBICIN FOR INJECTION 2 MG contains EPIRUBICIN HYDROCHLORIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02324091, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 24-Apr-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EPIRUBICIN FOR INJECTION used for?
Metastatic breast cancer; adjuvant treatment of early stage breast cancer; small cell and non-small cell lung cancer; non-Hodgkin's lymphoma; Hodgkin's disease; ovarian and gastric carcinoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Epirubicin cost around the world?
Epirubicin is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Hungary | producer price (ex-factory) | 3 | 6 | HUF███.██ |
| Romania | max producer price | 2 | 6 | RON███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
27 pack listings across 19 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Epirubicin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Epirubicin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Epirubicin, across 15 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 1 | 1 | EPIRUBICIN FOR INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION, PHARMORUBICIN RDF | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PHARMORUBICIN PFS, PMS-EPIRUBICIN | No marketed DIN |
| ACCORD HEALTHCARE INC 3535 Boulevard St-Charles, Suite 704 Kirkland Quebec Canada H9H 5B9 | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
| ADRIA LABORATORIES OF CANADA LTD. 2280 Argentia Road Mississauga Ontario Canada L5N 6H8 | 1 | 0 | PHARMORUBICIN RDF INJ 50MG/VIAL | No marketed DIN |
| FRESENIUS KABI CANADA LTD | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
| HOSPIRA HEALTHCARE ULC 17300 Trans-Canada Highway Kirkland Quebec Canada H9J 2M5 | 1 | 0 | EPIRUBICIN HYDROCHLORIDE FOR INJECTION | No marketed DIN |
| OMEGA LABORATORIES LIMITED | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
| PHARMACEUTICAL PARTNERS OF CANADA INC | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
| STRIDES PHARMA CANADA INC | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
| UMAN PHARMA INC | 1 | 0 | EPIRUBICIN HYDROCHLORIDE INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 2 mg/mL concentration). |
| Storage | Not explicitly detailed in provided text (Table of Contents points to page 19). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Epirubicin |
|---|---|
| ATC code | L01DB03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02324091 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2324091 |
| Brand name | EPIRUBICIN FOR INJECTION |
| Generic / active ingredient | EPIRUBICIN HYDROCHLORIDE : 2 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L01DB03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01DB |
| Current status | MARKETED |
| Status date | 24-Apr-2026 |
| Original market date | 2009-09-14 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered intravenously. Dosage varies by indication (e.g., metastatic breast cancer, adjuvant early breast cancer). Requires blood count and hepatic function monitoring.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to anthracyclines; marked persistent myelosuppression; severe hepatic impairment; severe myocardial insufficiency; recent MI; severe arrhythmias; history of severe cardiac disease.
Warnings and precautions
Potent drug; irreversible cardiac toxicity (cumulative dose limit 900-1000 mg/m2); secondary AML/MDS risk; severe myelosuppression; severe local tissue necrosis if extravasated.
Is Epirubicin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 17 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 15 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| EPIRUBICIN HYDROCHLORIDE FOR INJECTION | Strength | Powder For Solution | HOSPIRA HEALTHCARE ULC 17300 Trans-Canada Highway Kirkland Quebec Canada H9J 2M5 | CANCELLED POST MARKET | 02301067 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | 02413221 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2.0 MG | SOLUTION | FRESENIUS KABI CANADA LTD | DORMANT | 02312093 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | UMAN PHARMA INC | APPROVED | 02322242 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED PRE MARKET | 02323001 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02387379 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | OMEGA LABORATORIES LIMITED | APPROVED | 02409372 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02264927 |
| EPIRUBICIN HYDROCHLORIDE INJECTION | Strength | Solution | ACCORD HEALTHCARE INC 3535 Boulevard St-Charles, Suite 704 Kirkland Quebec Canada H9H 5B9 | CANCELLED POST MARKET | 02303892 |
| PHARMORUBICIN PFS | 2 MG | SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | 02065703 |
2 · Same class — other molecules in ATC L01DB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Doxorubicin | ADRIAMYCIN PFS · ADRIAMYCIN RDF · ADRIAMYCIN RDF INJ 10MG/VIAL · ADRIAMYCIN RDF INJ 150MG/VIAL · +13 more | 25 | 7 | Yes |
| Daunorubicin | CERUBIDINE · DAUNORUBICIN HYDROCHLORIDE FOR INJECTION · DAUNORUBICIN HYDROCHLORIDE INJECTION · DAUNORUBICIN INJECTABLE SOLUTION · +1 more | 6 | 3 | Yes |
| Epirubicin | EPIRUBICIN FOR INJECTION · EPIRUBICIN HYDROCHLORIDE FOR INJECTION · EPIRUBICIN HYDROCHLORIDE INJECTION · PHARMORUBICIN PFS · +3 more | 15 | 1 | Yes |
| Idarubicin | AJ-IDARUBICIN · IDAMYCIN - CAP 10MG · IDAMYCIN - CAP 25MG · IDAMYCIN - CAP 5MG · +7 more | 12 | 1 | Yes |
| Mitoxantrone | MITOXANTRONE INJECTION · MITOXANTRONE INJECTION USP · NOVANTRONE · NOVANTRONE INJ 2MG/ML | 5 | 1 | Yes |
| Valrubicin | VALTAXIN | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01DC | Bleomycin · Mitomycin | 13 | 5 |
| L01DA | Dactinomycin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is EPIRUBICIN FOR INJECTION called?
The same molecule, Epirubicin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Epirubicin Accord | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.